UCB's Global Corporate Website
Welcome to UCB in the United States
  • Healthcare Professionals
  • Patients
  • Investors

    • Categories

    Archives

    Jul

    21

    UCB announces U.S. availability of RYSTIGGO® (rozanolixizumab-noli) for the treatment of generalized myasthenia gravis (gMG) in adult patients who are anti-acetylcholine receptor (AChR) or anti-muscle-specific tyrosine kinase (MuSK) antibody positive

    Read More

    Jun

    27

    Fulfilling Our Ambition to Deliver an FDA-Approved Treatment for People Living with Generalized Myasthenia Gravis

    Read More

    Jun

    27

    UCB announces U.S. FDA approval of RYSTIGGO® (rozanolixizumab-noli) for the treatment of adults with generalized myasthenia gravis

    Read More

    Jun

    14

    Recognizing Ethical Leadership at UCB

    Read More

    Jun

    02

    Prioritizing Mental Health as a Caregiver to a Child With Dravet Syndrome

    Read More

    Jun

    01

    Myasthenia Gravis Awareness Month is the Time to Understand More About the Lived Experiences of the Community

    Read More

    Apr

    27

    Voices on Value: Breaking Down the Value Chain: The Policies Impacting Patients

    Read More

    Apr

    21

    Earth Day 2023: Our Commitment to Sustainability in the Workplace

    Read More

    Apr

    20

    UCB Showcases Strength and Depth of Neurology Portfolio at 75th American Academy of Neurology (AAN) Annual Meeting

    Read More

    Apr

    18

    How Shared Decision-Making Creates Better Patient-Provider Collaboration in Dermatology

    Read More